Find out about us through our annual reports, financial statements and reviews, or read other reports about our work.
This report aims to guide experts, communicators and practitioners to communicate with impact, so that the public understands and supports action on drug-resistant infections.
[Summary] This report aims to help experts and practitioners to communicate with impact, so that the public understands and supports action on drug-resistant infections.
Key outcomes from the second Call to Action on Antimicrobial Resistance held in Ghana, co-hosted by the Governments of Ghana, Thailand and the UK, along with the World Bank, UN Foundation and Wellcome.
This scientific white paper looks at the evidence about how antimicrobial resistance in the environment is impacting human health, and at how the risks can be addressed. It summarises discussions from the International Environmental AMR forum, held in April 2018.
A summary of the findings of our scientific white paper, which looks at the evidence about how antimicrobial resistance in the environment is impacting human health, and at how the risks can be addressed.
Recommendations from a pilot project to openly publish human antimicrobial resistance surveillance data generated and collected by the pharmaceutical industry. The project was led by the Open Data Institute and funded by Wellcome.
summary of the discussions at the forum, which looked at opportunities to better understand and help reduce the impact of environmental AMR on human health.
The key outcomes from the Call to Action on Antimicrobial Resistance event, organised by Wellcome in partnership with the UK, Ghanaian and Thai governments and the UN Foundation.
A summary of what’s been achieved in the last year since leaders met at the UN General Assembly 2016 and made declarations to commit to work on drug-resistant infections.
The results from our workshop exploring the use of clinical trial networks for antibiotic development and why they’re important.
Our infographics explore how a network could make clinical trials for antibiotics more effective, and how it could be sustained.
We propose concrete interventions to combat the real and growing threat of antimicrobial resistance.
A summary of the discussions at our summit on antimicrobial resistance, a review of the different policy options available, and supporting literature.
Nature comment piece by Jeremy Farrar and Sally Davies on antimicrobial resistance.
A summary of areas for immediate action, discussed at our summit on antimicrobial resistance.
We commissioned a review on antibiotic alternatives, which was published in The Lancet.
We examined the potential use of diagnostic tools to guide antibiotic use in a range of common clinical scenarios.
We commissioned Good Business to explore what the public think about antimicrobial resistance.